What is Godavari Drugs share price return in the past 10 years?

Godavari Drugs Ltd share price has appreciated 12.9% annually (CAGR) over the past ten years.

Godavari Drugs Ltd - Stock Valuation and Financial Performance

Name: Godavari Drugs
Brand: Godavari Drugs

BSE: 530317 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Godavari Drugs Share Price

₹113.50 -2.00 -1.73%
as on 21-Nov'24 16:59

DeciZen - make an informed investing decision on Godavari Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Godavari Drugs stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

13.17

Market Cap:

87 Cr.

52-wk low:

52-wk high:

155

Is Godavari Drugs Ltd an attractive stock to invest in?

1. Is Godavari Drugs Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Godavari Drugs Ltd is a average quality company.

2. Is Godavari Drugs Ltd undervalued or overvalued?

The key valuation ratios of Godavari Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Godavari Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Godavari Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Godavari Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	32.3%	15.8%	16.9%	11%	12.1%	11.8%	17.6%	18.4%	12.4%	12.6%	-
Value Creation Index ⓘ	1.3	0.1	0.2	-0.2	-0.1	-0.2	0.3	0.3	-0.1	-0.1	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	54.9	71.1	75.6	64.5	83.5	95.7	123	161	160	157	140
Sales YoY Gr.	-	29.7%	6.3%	-14.8%	29.6%	14.6%	28.2%	31.3%	-0.9%	-1.8%	-
Adj EPS ⓘ	4.6	1.7	1.7	0.8	1.6	2.6	5.3	7.2	6.5	7.6	8.8
YoY Gr.	-	-63.1%	2.4%	-53.2%	91.4%	68.4%	103.5%	35.2%	-9.6%	17.1%	-
BVPS (₹) ⓘ	17.3	19.1	21.5	22.6	24.2	26.9	32.4	39.4	44.4	51.7	55.4
Adj Net Profit ⓘ	3.5	1.3	1.3	0.6	1.2	2	4	5.4	4.9	5.7	7
Cash Flow from Ops. ⓘ	-5.9	-4.5	5.2	3.8	3.7	6.2	1.3	11.2	13.2	18.4	-
Debt/CF from Ops. ⓘ	-1.5	-3.4	3.1	5	5.9	4.4	22.9	2.1	4.3	3.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12.4%	13.4%	8.5%	-1.8%
Adj EPS ⓘ	5.8%	37.4%	12.7%	17.1%
BVPSⓘ	12.9%	16.4%	16.9%	16.6%
Share Price	12.9%	50.6%	25.4%	14.7%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	30.6	9.3	8.5	3.7	6.6	10.2	17.9	20	15.5	15.8	16.4
Op. Profit Mgn % ⓘ	10.6	6.4	7	6.3	6.6	6.3	8	7.2	7.4	8.6	10.1
Net Profit Mgn % ⓘ	6.3	1.8	1.7	1	1.4	2.1	3.3	3.4	3.1	3.7	4.7
Debt to Equity ⓘ	0.7	1.1	1	1.1	1.2	1.4	1.3	0.8	1.7	1.5	0.5
Working Cap Days ⓘ	98	154	180	249	221	219	188	157	179	200	114
Cash Conv. Cycle ⓘ	43	58	60	78	72	75	70	50	82	113	12

Recent Performance Summary

Net Profit is growing at healthy rate in last 3 years 12.70%

Return on Equity has declined versus last 3 years average to 16.40%

Sales growth has been subdued in last 3 years 8.51%

Debt to equity has increased versus last 3 years average to 1.48

Sales growth is not so good in last 4 quarters at -7.40%

Latest Financials - Godavari Drugs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	8.8	-
TTM Sales (₹ Cr.)	140	-
BVPS (₹.) ⓘ	55.4	-
Reserves (₹ Cr.) ⓘ	34	-
P/BV ⓘ	2.09	-
PE ⓘ	13.17	-

From the Market
52 Week Low / High (₹)	86.99 / 155.00
All Time Low / High (₹)	1.00 / 155.00
Market Cap (₹ Cr.)	87
Equity (₹ Cr.)	7.5
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Godavari Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

5.11

1.25

0.12

1.25

0.25

* Pledged shares as % of Promoter's holding (%)

Valuation of Godavari Drugs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Godavari Drugs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	54.85	71.12	75.60	64.45	83.54	95.70	122.67	161.11	159.62	156.71
Operating Expenses ⓘ	49.06	66.63	70.37	60.39	78.06	89.66	112.83	149.82	149.70	143.41
Manufacturing Costs	5.06	3.94	6.67	5.38	6.01	6.10	8.17	9.89	10.22	11.91
Material Costs	40.41	58.68	58.94	49.27	64.91	76.67	96.59	130.46	128.06	120.81
Employee Cost	2.01	2.17	2.38	2.67	3.45	3.45	3.94	4.96	4.84	5.13
Other Costs ⓘ	1.58	1.84	2.37	3.06	3.68	3.44	4.13	4.51	6.59	5.55
Operating Profit ⓘ	5.78	4.50	5.23	4.06	5.49	6.04	9.84	11.29	9.92	13.30
Operating Profit Margin (%)	10.5%	6.3%	6.9%	6.3%	6.6%	6.3%	8.0%	7.0%	6.2%	8.5%
Other Income ⓘ	0.30	0.19	0.80	0.68	0.24	0.33	0.41	0.28	0.66	0.62
Interest ⓘ	0.67	1.88	2.52	2.44	2.90	2.91	3.32	2.85	3.93	4.92
Depreciation ⓘ	0.68	0.63	0.81	0.99	1.09	1.16	1.22	1.70	1.94	1.99
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0.23	-0.09
Profit Before Tax ⓘ	4.73	2.18	2.71	1.31	1.75	2.29	5.71	7.02	4.93	6.92
Tax ⓘ	1.09	0.83	0.90	0.48	0.54	0.29	1.58	1.78	1.15	1.37
Profit After Tax	3.65	1.35	1.81	0.83	1.21	2	4.13	5.25	3.79	5.55
PAT Margin (%)	6.6%	1.9%	2.4%	1.3%	1.4%	2.1%	3.4%	3.3%	2.4%	3.5%
Adjusted EPS (₹)	4.8	1.8	2.4	1.1	1.6	2.7	5.5	7.0	5.0	7.4
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	13.06	14.41	16.22	17.05	18.26	20.26	24.39	29.63	33.42	38.97
Share Capital ⓘ	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53	7.53
Reserves ⓘ	5.53	6.88	8.69	9.52	10.73	12.73	16.86	22.10	25.89	31.44
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	8.48	15.48	15.72	18.14	21.01	26.08	28.08	20.34	54.97	55.62
Long Term Debt	3.64	3.92	4.39	6.60	8.01	11.16	14.49	11.78	11.95	11.17
Short Term Debt	4.84	11.56	11.33	11.54	13	14.91	13.59	8.56	43.02	44.46
Trade Payables	8.78	17.36	20.06	23.02	30.36	30.27	29.50	43.32	24.67	31.63
Others Liabilities ⓘ	4.42	3.30	3.70	4.82	4.10	7.31	9.17	8.12	8.37	8.53
Total Liabilities ⓘ	34.74	50.54	55.70	63.02	73.74	83.92	91.14	101.41	121.43	134.75
Fixed Assets
Gross Block	23.11	25.08	29.93	32.70	34.20	34.21	44.05	49.57	46.28	46.88
Accumulated Depreciation	15.83	16.35	17.16	18.15	19.23	20.40	21.62	23.32	21.37	20.19
Net Fixed Assetsⓘ	7.28	8.73	12.77	14.56	14.97	13.81	22.43	26.25	24.91	26.68
CWIP ⓘ	0.42	1.20	0.12	0.97	2.05	8.93	0.76	0.49	9.08	18.32
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	9.28	10.74	11.32	13.47	16.47	17.75	14.65	10.03	19.86	20.65
Trade Receivables	13.13	24.55	24.17	26.78	33.96	36.02	45.12	55.58	57.93	59.42
Cash Equivalents	0.26	0.65	0.88	1.62	1.53	1.43	1.64	2.28	3.08	2.62
Others Assetsⓘ	4.38	4.68	6.44	5.64	4.77	5.98	6.54	6.78	6.57	7.05
Total Assets ⓘ	34.74	50.54	55.70	63.02	73.74	83.92	91.14	101.41	121.43	134.75

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-5.85	-4.53	5.15	3.82	3.71	6.24	1.33	11.23	13.22	18.41
PBT ⓘ	3.65	1.35	2.71	1.31	5.72	2.29	5.69	7.02	4.93	6.92
Adjustment ⓘ	2.42	0.56	2.51	2.73	-0.24	3.75	4.13	4.27	5.22	6.29
Changes in Working Capital ⓘ	-11.5	-5.66	0.43	0.35	-1.49	0.6	-6.92	1.72	4.29	6.22
Tax Paid ⓘ	0	0	-0.50	-0.57	-0.28	-0.39	-1.58	-1.78	-1.23	-1.02
Cash Flow From Investing Activity ⓘ	-0.20	-2.08	-2.97	-2.95	-2.34	-6.68	-1.25	-4.97	-8.64	-13.22
Capex	-0.20	-2.08	-3.77	-3.62	-2.58	-6.89	-1.67	-5.25	-9.19	-13.01
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0.80	0.68	0.24	0.21	0.42	0.27	0.55	-0.21
Cash Flow From Financing Activityⓘ	6.07	6.99	-1.95	-0.14	-1.46	0.34	0.13	-5.62	-3.77	-5.65
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	1.23	0.15	0.47	2.21	1.41	3.15	3.33	-2.71	0.17	-0.78
Interest Paid ⓘ	0	0	-2.51	-2.42	-2.89	-2.91	-3.31	-2.85	-3.93	-4.91
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	4.84	6.85	0.09	0.06	0.01	0.10	0.12	-0.06	-0.01	0.04
Net Cash Flow ⓘ	0.01	0.39	0.23	0.73	-0.09	-0.10	0.21	0.64	0.81	-0.46

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	32.32	9.84	11.81	4.99	6.85	10.39	18.49	19.42	12.01	15.33
ROCE (%)	32.3	15.77	16.89	11.01	12.14	11.8	17.58	18.35	12.36	12.63
Asset Turnover Ratio	2.48	1.86	1.56	1.09	1.22	1.21	1.4	1.67	1.43	1.22
PAT to CFO Conversion(x)	-1.6	-3.36	2.85	4.6	3.07	3.12	0.32	2.14	3.49	3.32
Working Capital Days
Receivable Days	40	87	107	144	133	133	121	114	130	137
Inventory Days	37	46	49	70	65	65	48	28	34	47
Payable Days	42	81	116	160	150	144	113	102	97	85

Godavari Drugs Ltd Stock News

Godavari Drugs Ltd FAQs

What is the share price of Godavari Drugs?

Company share prices are keep on changing according to the market conditions. The closing price of Godavari Drugs on 21-Nov-2024 16:59 is ₹113.5.

What is the market cap of Godavari Drugs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Godavari Drugs stood at ₹86.98.

What is the P/E ratio of Godavari Drugs?

The latest P/E ratio of Godavari Drugs as of 21-Nov-2024 16:59 is 13.17.

What is the P/B ratio of Godavari Drugs?

The latest P/B ratio of Godavari Drugs as of 21-Nov-2024 16:59 is 2.09.

What is the 52-week high and low of Godavari Drugs?

The 52-week high of Godavari Drugs is ₹155.0 and the 52-week low is ₹86.99.

What is the TTM revenue of Godavari Drugs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Godavari Drugs is ₹140.1 ( Cr.) .

About Godavari Drugs Ltd

Godavari Drugs was incorporated as a private limited company on December 2, 1987 and subsequently converted into a public limited company on September 25, 1992. It was promoted by Ghanshyam Jaju, Mukund Kakani and PC Shrimal.

The company has set up a project to manufacture 180 TPA at Sulphamethoxazole (SMX) in 1988. The project is located at Maharashtra Industrial Development Corporation (MIDC), Nanded, a notified class â€˜Câ€™ backward district in Maharashtra. The project was fully commissioned on July 3, 1989.

The registered office of the company is located at Secunderabad in Andhra Pradesh and Mukund Kakani is its Managing Director.

Business area of the company

The companyâ€™s principal activity is to manufacture and sell bulk drugs. It undertakes contract manufacturing from various organizations. The products include Pyrazinamide and Ethambutol HCL.